Delineation guidelines for the lymphatic target volumes in 'prone crawl' radiotherapy treatment position for breast cancer patients.
Breast
/ pathology
Breast Neoplasms
/ radiotherapy
Female
Humans
Lymph Nodes
/ pathology
Lymphatic Metastasis
/ pathology
Magnetic Resonance Imaging
/ methods
Patient Positioning
/ methods
Practice Guidelines as Topic
Radiotherapy
/ standards
Radiotherapy Planning, Computer-Assisted
/ methods
Supine Position
Tomography, X-Ray Computed
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 11 2021
18 11 2021
Historique:
received:
04
06
2021
accepted:
01
11
2021
entrez:
19
11
2021
pubmed:
20
11
2021
medline:
26
2
2022
Statut:
epublish
Résumé
Our recently developed prone crawl position (PCP) for radiotherapy of breast cancer patients with lymphatic involvement showed promising preliminary data and it is being optimized for clinical use. An important aspect in this process is making new, position specific delineation guidelines to ensure delineation (for treatment planning) is uniform across different centers. The existing ESTRO and PROCAB guidelines for supine position (SP) were adapted for PCP. Nine volunteers were MRI scanned in both SP and PCP. Lymph node regions were delineated in SP using the existing ESTRO and PROCAB guidelines and were then translated to PCP, based on the observed changes in reference structure position. Nine PCP patient CT scans were used to verify if the new reference structures were consistently identified and easily applicable on different patient CT scans. Based on these data, a team of specialists in anatomy, CT- and MRI radiology and radiation oncology postulated the final guidelines. By taking the ESTRO and PROCAB guidelines for SP into account and by using a relatively big number of datasets, these new PCP specific guidelines incorporate anatomical variability between patients. The guidelines are easily and consistently applicable, even for people with limited previous experience with delineations in PCP.
Identifiants
pubmed: 34795352
doi: 10.1038/s41598-021-01841-y
pii: 10.1038/s41598-021-01841-y
pmc: PMC8602302
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
22529Subventions
Organisme : Bijzonder Onderzoeksfonds UGent
ID : BOFSTG2018002501
Informations de copyright
© 2021. The Author(s).
Références
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Radiother Oncol. 2015 Jan;114(1):3-10
pubmed: 25630428
Acta Oncol. 2013 May;52(4):703-10
pubmed: 23421926
Radiother Oncol. 2016 Jan;118(1):205-8
pubmed: 26791404
Radiother Oncol. 2015 Jan;114(1):11-6
pubmed: 25466373
Radiother Oncol. 2004 Jun;71(3):287-95
pubmed: 15172144
Ann Anat. 2020 Nov;232:151562
pubmed: 32562859
Front Oncol. 2011 Oct 11;1:31
pubmed: 22655240
Radiat Oncol. 2017 May 26;12(1):89
pubmed: 28549483
N Engl J Med. 2015 Jul 23;373(4):307-16
pubmed: 26200977
N Engl J Med. 2015 Jul 23;373(4):317-27
pubmed: 26200978
Lancet. 2014 Jun 21;383(9935):2127-35
pubmed: 24656685
N Engl J Med. 2013 Mar 14;368(11):987-98
pubmed: 23484825
Breast Care (Basel). 2020 Apr;15(2):128-135
pubmed: 32398981
Radiother Oncol. 2014 Jun;111(3):366-73
pubmed: 24909095
Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):745-51
pubmed: 18687534
J Appl Clin Med Phys. 2017 Jul;18(4):200-205
pubmed: 28649708
Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):437-448
pubmed: 32334035